Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.62M fell 9.5% year over year, behind the -7.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +13.7% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -6.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.62M-1.2% QoQ
- Last fiscal yearDec 2025
- $18.95M-6.3% YoY
- LTMMar 2026
- $18.46M-7.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.5% | -100.0% | -90.5 pp |
| 1 year | -6.3% | -100.0% | -93.7 pp |
| 3-year CAGR | +13.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 18.95M USD
- Year-over-year change
- -6.3%
- 4-year CAGR
- +27.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.95M | -6.3% |
| FY2024 | 2024-12-31 | 20.22M | +7.4% |
| FY2023 | 2023-12-31 | 18.82M | +46.2% |
| FY2022 | 2022-12-31 | 12.88M | +76.9% |
| FY2021 | 2021-12-31 | 7.28M | — |
Selling, General & Admin vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 selling, general & admin of $18.46M is the 9th highest of the 10 companies compared; the peer median is $40.57M.
- Its year-over-year change of -7.7% is the 4th highest of 10, against a peer median of -21.8%.
- Over three fiscal years its annual growth of +13.7% compares with a peer median of -12.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46B | +48531.9% | -28.7% | — | |
| LTM Mar 2026 | $47.37M | -20.9% | -4.0% | 257.2% | |
| LTM Mar 2026 | $45.53M | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $42.34M | -49.3% | -18.0% | 670.4% | |
| LTM Mar 2026 | $40.57M | -24.5% | -6.8% | 269.8% | |
| LTM Mar 2026 | $35.34M | -27.5% | -17.7% | 3080.9% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M | +8.6% | +44.6% | 180.0% |
| LTM Mar 2026 | $19.24M | -21.8% | -16.6% | 35.1% | |
| LTM Mar 2026 | $18.46M | -7.7% | +13.7% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $12.2M | +39.9% | +47.3% | — |
| Peer median (excluding ABOS) | $40.57M | -21.8% | -12.4% | 257.2% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| Weighted Avg Shares | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M |
| Weighted Avg Shares (Diluted) | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.